Filing Overview
This Form 8-K was filed by Blue Water Biotech, Inc. on August 22, 2023, reporting events occurring August 16, 2023. The request identifies Onconetix, Inc.; however, the filing text identifies the registrant as Blue Water Biotech, Inc., trading under BWV.
Business and Management Changes
- Joseph Hernandez resigned effective August 16, 2023 as Chairman, Chief Executive Officer, and a member of the Board.
- The Company stated that it is reviewing its and Mr. Hernandez’s respective rights and obligations related to the resignation.
- James Sapirstein, an existing director, was appointed Interim Executive Chairman effective September 30, 2023. Until that appointment, he will serve as Lead Independent Director.
- Upon becoming Interim Executive Chairman, Mr. Sapirstein will leave the Audit, Compensation, and Nominating and Corporate Governance Committees.
- Mr. Sapirstein will receive $25,000 per month for his service as Interim Executive Chairman and, pending that appointment, Lead Independent Director.
- Chief Financial Officer Jon Garfield was appointed interim principal executive officer effective August 16, 2023, with general supervision and direction of the Company’s business and affairs during the interim period.
Financial Metrics and Liquidity
This filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial performance metrics.
Material Review and Unusual Items
The Board’s Audit Committee commenced an independent review of employee expenditures and their classification. The Committee expected to complete the review as soon as practicable. The filing does not disclose the scope, financial impact, findings, or anticipated adjustments from the review.
Guidance, Outlook, and Risks
No financial guidance or operating outlook was provided. Key disclosed uncertainties include the outcome of the employee-expenditure review and the rights and obligations associated with Mr. Hernandez’s resignation.
Investor Verification Items
- Confirm the registrant’s identity, given the discrepancy between the requested company name and the filing’s identification of Blue Water Biotech, Inc.
- Monitor the Audit Committee’s independent review and any resulting accounting revisions, control issues, or financial disclosures.
- Review subsequent filings for the permanent appointment of executive leadership and any changes to compensation or governance.
- Verify whether the former CEO’s resignation results in contractual, severance, litigation, or other liabilities.